This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. (25th April 2018)
Record Type:
Journal Article
Title:
172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. (25th April 2018)
Main Title:
172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2